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higher than that of the ﬁrst visit (p < 0.000). We tested the null that the coefﬁcient 
on the number of visit is equal to zero. We rejected the null hypothesis that the coef-
ﬁcient on the number of visits dummy variable is equal to zero (p < 0.000). CONCLU-
SIONS: Our study ﬁnds that return visits are associated with higher patient satisfaction 
than ﬁrst visit. Furthermore, the dummy variable of the number of visit explains 
patient satisfaction score well.
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EIGHT KEY EVIDENCES FOR CONTENT VALIDITY OF PATIENT 
REPORTED OUTCOME (PRO) INSTRUMENTS
Martin ML
Health Research Associates, Inc, Seattle, WA, USA
OBJECTIVES: The FDA Guidance on the development and use of Patient Reported 
Outcome (PRO) instruments emphasizes the need to establish content validity for the 
concepts addressed by the PRO items. Content validity is the relationship between an 
instrument’s content and the construct it intends to measure. This paper presents eight 
key points of criteria for supporting evidences of content validity for PRO instruments. 
METHODS: Language is the primary means of patient recognition and expression of 
concepts. Concept relevance is assessed by qualitative analysis. A Concept Elicitation 
process is used to describe the relationship between concepts and patient experience. 
Patient comprehension of a concept is evaluated through cognitive interviews. The 
design of interviews and treatment of results must focus on speciﬁc criteria in order 
to support content validity of the PRO. RESULTS: The eight key criteria required to 
support PRO content validity are: (1) concepts are relevant to the patient experience 
with their condition; (2) qualitative data collection has been conducted to the point 
of “saturation of concept” (3) concepts are presented in the langua ge of the patients; 
(4) the appropriate aspect of the concept is being evaluated; (5) the presentation 
of the concept in a PRO can be properly comprehended by patients; (6) response 
options are meaningful and clear; (7) the recall period is appropriate to the patient 
experience of their condition; and (8) the concepts and language used in the PRO are 
adaptable for use in global trials. This paper presents examples of data collection, and 
documentation for each criterion. CONCLUSIONS: Evidences of content validity are 
can only be provided by qualitative data. The qualitative interview process may vary 
in speciﬁc methods but should adhere to consistent objectives, and should cover at 
least eight key evidences in order to provide adequate support for content validity of 
a PRO.
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AN EVALUATION OF THE STATISTICAL EFFICIENCY OF THE US 
POPULATION MEDIAN-BASED EQ-5D INDEX USING DATA FROM THE 
MEDICAL EXPENDITURE PANEL SURVEY
Luo X, Shaw JW, Pickard AS, Walton S
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: An algorithm was recently developed to predict median US population 
preferences for EQ-5D health states. The primary objective of this study was to 
provide evidence regarding the estimation efﬁciency of the median-based EQ-5D index 
relative to the existing mean-based index. A secondary objective was to evaluate the 
sensitivity of ﬁndings to the application of robust statistical procedures. METHODS: 
Data were taken from the 2002–2003 Medical Expenditure Panel Survey. Adult survey 
participants completed the EQ-5D and 12-item Short-Form Health Survey (SF-12); 
rated their physical and mental health; and reported the presence of chronic condi-
tions. Associations of mean- and median-based EQ-5D index scores with health status 
measures and chronic conditions were estimated using least squares (LS) and rank (R) 
regression. Associations of changes in index scores with changes in health status 
measures were similarly estimated. For each set of analyses, a relative efﬁciency (RE) 
statistic was derived as the ratio of model F statistics (median-based index/mean-based 
index). RESULTS: RE statistics (LS/R) for associations of index scores with health 
status measures and chronic conditions were as follows: SF-12 mental summary, 
0.50/1.35; SF-12 physical summary, 0.40/0.75; mental health rating, 0.63/1.10; physi-
cal health rating, 0.54/0.99; angina, 0.55/0.89; arthritis, 0.50/0.88; asthma, 0.77/0.98; 
coronary heart disease, 0.54/0.91; diabetes, 0.60/0.95; emphysema, 0.65/1.03; hearing 
problems, 0.50/0.98; myocardial infarction, 0.51/0.97; stroke, 0.66/1.00; and visual 
problems, 0.65/1.03. RE statistics (LS/R) for associations of index score changes with 
changes in SF-12 physical and mental summaries were 0.63/0.89 and 0.59/1.17, 
respectively. CONCLUSIONS: Parametric analyses exhibited reduced power when 
applied to the median-based index scores. However, robust procedures suffered from 
minimal efﬁciency losses and exhibited efﬁciency gains when used to analyze associa-
tions of index scores with mental health measures. These ﬁndings reﬂect the difference 
in skewness between the mean- and median-based index scores, which can be attrib-
uted to the difference in score ranges.
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INTEGRATED INTERPRETATION OF KAPPA WITH SENSITIVITY AND 
SPECIFICITY
Shimbo T1, Miyaki K1, Sakai M1, Takahashi O2, Ishizuka N1
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OBJECTIVES: The reproducibility (kappa) and accuracy (sensitivity/speciﬁcity: SN/SP) 
of diagnostic tests has often been reported. However, both values are discussed sepa-
rately, even when simultaneously determined. Because good reproducibility is the 
premise for good accuracy, integrated interpretation of both is required. The present 
study investigates the relationship between kappa and measured SN/SP by Monte-
Carlo simulation given true accuracy and measurement error. METHODS: We 
assumed diseased and non-diseased populations with test values that are normally 
distributed with different means and the same standard deviation. True SN/SP given by 
a threshold value is decreased by the measurement error that is also normally distrib-
uted and this leads to measured SN/SP. We assumed that sensitivity equals speciﬁcity 
for convenience. Two measurements can generate kappa statistics. We simulated this 
process using Monte-Carlo simulation. The true mean difference of both the population 
and the standard deviation of measurement error was changed for a variety of combina-
tions then kappa and measured SN/SP were compared. We assumed a total population 
of 100,000, and disease prevalences of 10% and 50%. Simulation was done in STATA 
10/SE. RESULTS: Disease prevalence did not substantially affect the results, so only the 
results for 10% prevalence are described. At a true SN/SP of 93.1% and kappa values 
of 0.75, 0.5 and 0.25, measured SN/SP decreased to 91.3%, 86.1% and 77.1%, respec-
tively. At a true SN/SP of 68.9% and kappa values of 0.75, 0.5, 0.25, measured SN/SP 
decreased to 68.3%, 66.0%, 61.7%, respectively. Now we know measured SN/SP can 
substantially or not improve so much when kappa improves, depending on the combi-
nation of kappa and measured SN/SP. CONCLUSIONS: The relationship between 
kappa and SN/SP allows the integrated interpretation of both, and indicates how much 
accuracy can be improved by improving reproducibility.
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COMPARISON OF DIFFERENCE-IN-DIFFERENCE AND PROPENSITY 
SCORE METHODS IN REGRESSIONS WITH BINARY OUTCOMES
Cao Z1, Margolis J2, Mark T3
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Bala Cynwyd, PA, USA, 
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OBJECTIVES: Difference-in-difference (DID) and propensity score matching (PSM) 
methods are two ways of evaluating the effect of changes in policies inﬂuencing drug 
prescribing or medications. The objective of this study is to compare and contrast the 
strengths and weakness and different types of information provided by the DID and 
PSM methods in the context of determining the impact of an insurance plan restriction 
on binary health care utilization outcomes. Adult patients diagnosed with diagnosis 
A were selected from MarketScan® Commercial Database (2005–2007), a large claims 
data form persons with employ-based insurance. METHODS: The DID analysis was 
implemented by a GEE regression with logit link, binomial variance function, and 
exchangeable correlation structure on panel data with pre- and post-restriction period. 
The dependent variables included inpatient hospitalization, ER visit, use of alternative 
drug B, and use of alternative drug C. The key independent variables included an 
indicator for plan restriction, an indicator for pre- or post- restriction period, and an 
interaction term between them. Demographic and clinical characteristics were included 
as covariates. The odds ratios (OR) of the interaction terms were considered as the 
DID estimates. In the PSM method, patients in restricted and unrestricted plans were 
propensity score matched based on pre-implementation characteristics, followed by 
logistic regressions. RESULTS: Without controlling for any covariate, the restriction 
effects were non-signiﬁcant on all outcomes using DID analysis. The restriction effects 
were signiﬁcant for ER visit and hospitalization using PSM. When all characteristics 
were controlled, the restriction effects were non-signiﬁcant in both methods, except 
the outcome of drug B use. CONCLUSIONS: DID and PSM- based methods may 
produce different estimates. Neither method can fully control all potential confound-
ers. Compared with the PSM method, DID method uses same individual as the control, 
but is restricted to studies when pre- and post-event data are available.
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STATISTICAL METHODS NEEDED IN HEALTH ECONOMICS
Gause D, Gause P
See-It-Analytics, Easton , PA, USA
OBJECTIVES: To review important statistical methods used in health economics. 
BACKGROUND: During two decades in health economics at Novartis Pharmaceuti-
cals, statistician Doug Gause regularly presented friendly one-page illustrations of 
statistical concepts in health economics. Thirty of these “Analysis Notes” are presented 
on this poster, along with a magnifying glass for easier viewing. ANALYSIS NOTES: 
Making inferences: Conﬁdence interval estimation instead of hypothesis testing, and 
bootstrapping to avoid assumptions. Analyzing costs: Two-part GLM models instead 
of transformations. Measuring compliance: Avoiding adherence bias in calculating 
MPR. Competing risks of discontinuing, adding, switching, or remaining on drug. 
Data visualization: Regression trees, drug-o-grams, mosaic plots, parallel coordinate 
plots, and sequence plots to visualize patterns. (Lets reserve pie charts for the Baker’s 
Convention !) Covariate adjustment: Marginal means/IPTW, confounders vs. collid-
ers, instrument variables, and time dependent covariates to incorporate changes over 
time. Historical data: Bayesian analysis for bias adjusting, and meta-analysis to incor-
porate results from multiple studies. Avoiding pitfalls: Be aware of the “individual-
ized” fallacy and the “ecological” fallacy. Differential follow-up: Person-time and 
survival analysis to accommodate censoring. Predictive modeling: Nearest neighbor 
vs. recursive partitioning vs. neural networks. Project planning: Sample size to han-
dling multiplicity. Clustered/longitudinal data: Random effects models to account for 
correlated observations from the same physician or repeated measurements from the 
same patient. Cost-effectiveness: Angles instead of ratios, and incremental net beneﬁt 
to handle multiple effectiveness measures. Heterogeneous data: Quantile and polyto-
mous regression to compare different MPR distributions. CONCLUSIONS: Statistics 
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needs to be taught in small friendly doses tied to practical problems. Each analysis 
note presented by Doug Gause has sketches drawn by artist Pat Gause.
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METHODS FOR IDENTIFYING CASE REPORTS OF SUSPECTED ADVERSE 
DRUG REACTIONS: AN EVALUATION OF THE EFFICIENCY OF 
ALTERNATIVE SEARCH STRATEGIES IN MEDLINE AND EMBASE
Michels SL, Ward A, Jones N
United BioSource Corp., Lexington, MA, USA
To illustrate the precision and sensitivity of identifying case reports of adverse events 
(AE) in MEDLINE and EMBASE, eight searching methods were created and applied 
to two systematic reviews of case reports. Search methods included use of indexing 
and text words for synonyms of AE and related terms, as well as drug, disease and 
study design. All eight methods contained the drug and combinations of other search 
strings and ranged from broad to very speciﬁc. Searches were developed for MEDLINE 
and EMBASE; duplicates were removed. Results from each approach were checked 
against a “gold standard” (GS) of case reports previously identiﬁed in two systematic 
reviews (75 anti-TNF agent, 57 baclofen case reports). Sensitivity and precision of 
each method were calculated. The broadest search, using drug terms alone, yielded 
over 11,000 and over 3,600 references for each systematic review topic. Sensitivity 
decreased as search methods became narrower; precision was consistently low (gener-
ally <6%). The search method for drug terms alone had 100% sensitivity for both 
systematic review topics with very low precision (<1.6%). Precision was highest when 
drug, disease, case report and AE were combined for baclofen (15%) with low sensitiv-
ity (26%). Of the GS articles available from MEDLINE, 7% and 18% of anti-TNF 
agent and baclofen case reports respectively were not indexed as case reports. Sensitive 
search methods able to identify relevant case reports are important, but when a sensi-
tive search was constructed, this lead to low precision. A sensitive search method must 
be broad, and search both databases. Precision remains low with each combination 
of approaches, making accurate identiﬁcation of case reports rather labor intensive. 
This illustration demonstrated the extent to which decisions made when developing 
search methods impact the comprehensiveness of reviews. Further work is on-going 
to conﬁrm the generalizability of these ﬁndings to other drugs.
CANCER – Clinical Outcomes Studies
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USE OF WHITE BLOOD CELL GROWTH FACTORS AND RISK OF 
ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES 
AMONG ELDERLY NON-HODGKIN’S LYMPHOMA PATIENTS
Gruschkus SK1, Lairson D2, Dunn JK3, Risser JM3, Du XL3
1Healthcare Informatics, a service of US Oncology, The Woodlands, TX, USA, 2University of 
Texas School of Public Health, Houston, TX, USA, 3University of Texas Houston School of 
Public Health, Houston, TX, USA
OBJECTIVES: Therapy-related myelodysplastic syndromes and acute myeloid leuke-
mia (t-MDS/AML) are devastating long-term complications of cancer therapy. Evi-
dence suggests that white blood cell growth factors (CSFs) may increase risk of t-MDS/
AML among patients (pts) receiving chemotherapy, possibly because they stimulate 
the proliferation and differentiation of hematopoietic stem cells and also interfere with 
apoptosis. The purpose of this retrospective study was to evaluate the association 
between CSF use and t-MDS/AML among a large population-based cohort of elderly 
non-Hodgkin’s lymphoma (NHL) pts treated with chemotherapy. METHODS: NHL 
pts were identiﬁed from the Surveillance, Epidemiology, and End Results-Medicare 
database diagnosed from 1992 to 2002 who received chemotherapy within 12 months 
of diagnosis. Pts were followed from their initial chemotherapy until t-MDS/AML 
development, death, or end of study period (December 31, 2006). Kaplan-Meier and 
Cox proportional hazards analyses were used to evaluate the association between CSF 
use and t-MDS/AML. RESULTS: A total of 13,203 pts were identiﬁed. Overall, 40% 
(n = 5,266) received CSF. 272 (5.2%) pts receiving CSF developed t-MDS/AML vs. 
230 (2.9%) who did not receive CSF (log-rank p < 0.0001). In a multivariable Cox 
regression analysis adjusting for gender, histology, stage, comorbidities, chemotherapy 
dates, and chemotherapy agent, CSF use was independently associated with a 53% 
increased risk of t-MDS/AML (HR 1.53; 95% CI 1.26–1.84). A dose-response rela-
tionship was observed, with t-MDS/AML risk increasing by quartile of CSF claims. 
In an evaluation of plausible biologic interactions, we found that pts receiving CSF 
and antimetabolite chemotherapy (n = 1,567 pts) had a 2.5 fold increased risk of 
t-MDS/AML (HR 2.49; 95% CI 1.91–3.26) vs. pts who received neither agent (p-inter-
action = 0.04). CONCLUSIONS: Our ﬁndings suggest that CSF use among elderly 
NHL chemotherapy pts chemo may increase risk of t-MDS/AML, even though abso-
lute risk is low. Future studies are necessary to verify these results and to determine 
the clinical implications of the observed interaction between CSF use and antimetabo-
lite chemotherapy.
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DIABETIC MEDICATIONS AND ITS ASSOCIATION WITH MORTALITY 
IN HOSPITALIZED CANCER PATIENTS
Nowshad G1, Alam S2, Shah P3, Salahudeen A4
1University of Texas, School of Public Health, Houston, TX, USA, 2School of Public Health, 
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OBJECTIVES: The effect of diabetes and diabetic medications on the morbidity and 
mortality in hospitalized cancer patients is a serious concern. We examined the asso-
ciation of diabetic medications with the transfer to ICU and inpatient mortality. 
METHODS: Electronic patient records were prospectively collected in 5489 hospital-
izations to UT MD Anderson Cancer Center from May 1st, to July 31st, 2006. For 
each patient demographic, laboratory and pharmacy data were obtained. To observe 
the effect of diabetic medications, we selected only diabetic patients, which were 
36.3% (1991) of the total hospitalization. Descriptive and logistic regression analyses 
were performed. RESULTS: Out of 1991 hospitalizations for diabetic cancer patients, 
ﬁfty seven percent were male, sixty nine percent were White with median age of sixty 
one. These patients were on different diabetic medications and thirty one percent were 
only on sliding scale insulin (SSI).After controlling for socio-demographic variables 
and other medications like chemotherapy, we found cancer patients who were only 
on SSI were more likely to be transferred to intensive care unit (ICU), (OR 2.31, CI: 
1.7–3.2; P < 0.001) and die during hospitalization (OR 1.88, CI: 1.3–2.7; P < 0.001). 
Glucocorticoids administration was also signiﬁcantly associated with inpatients mor-
tality (OR 5.91, CI: 3.5–9.8; (p < 0.00)). CONCLUSIONS: We found strong associa-
tions between the method of administration of insulin (SSI) and transfer to ICU and 
inpatient mortality in cancer patients with diabetes. Drug dosage and administration 
in inpatient settings should be tailored to the need of the patients to optimize the 
medication effect and minimize the side effects.
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RELIABILITY OF CLINICIAN VS. CLINICIAN ADVERSE SYMPTOM 
REPORTING
Atkinson TM1, Sit L1, Coffey C2, Shaw M1, Fruscione M1, Lavene D1, Gönen M1, Li Y1, 
Basch E1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2University of Kansas 
Medical Center, Lawrence, KS, USA
OBJECTIVES: Adverse symptom reporting is essential in clinical trials and drug label-
ing to assess and ensure patient safety. The standard approach to collecting adverse 
symptoms in cancer trials is clinician reporting using the Common Terminology 
Criteria for Adverse Events (CTCAE), which rates symptoms based upon descriptive 
clinical criteria. Despite the importance of this information, the reliability of these 
ratings has not been veriﬁed. At Memorial Sloan-Kettering Cancer Center, patients 
are routinely evaluated via CTCAE items by a clinician in an ofﬁce suite, and again 
shortly thereafter by a second clinician in a chemotherapy suite, with no information 
passed between clinicians. METHODS: To measure the reliability of these evaluations, 
a retrospective analysis of medical charts was completed in a sample of 433 patients 
aged 26–91 (M = 62.39; 41.8% male) receiving chemotherapy, who were enrolled in 
an observational study conducted between March 2005 and August 2009. Cancer 
diagnoses included lung (N = 153), prostate (N = 127), and gynecologic (N = 153). 
RESULTS: For the ﬁrst post-chemotherapy visit, intraclass correlation coefﬁcients 
were moderate for fatigue (0.52), dyspnea (0.75), nausea (0.55), vomiting (0.50), 
diarrhea (0.63), constipation (0.48) and neuropathy (0.73). The average time between 
evaluations was 70.42 minutes (range 67.97–72.88). These values were stable over up 
to six subsequent visits and did not differ based on age, gender, or elapsed time 
between evaluations. CONCLUSIONS: Given the short period of time and lack of 
interventions between reporting time points, the most likely cause of this lower than 
expected agreement between different clinicians is limited reliability of clinician report-
ing of this information. This ﬁnding has implications to clinical trials, as it brings into 
question the reliability or accuracy of symptom safety information. The investigators 
are currently evaluating patient-reported outcomes as an alternative and potentially 
more reliable method for collecting this information.
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INSULINS AND RISK OF CANCER AMONG TYPE 2 DIABETICS:  
A SYSTEMATIC REVIEW
Lu Z, Weiss Smith S
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: There have been reports which suggest that insulin glargine use may 
contribute to increased cancer risk in some type 2 diabetic populations, in addition 
to the fact that diabetes mellitus is also associated with certain types of cancer. There-
fore, the objective of the present study is to conduct a review of published studies on 
insulins and the risk of cancer in patients with type 2 diabetes and summarize the 
ﬁndings. METHODS: Several databases such as Medline and PubMed were used for 
publication searching. Key words included insulin, tumor, cancer, type 2 diabetes, and 
speciﬁc insulin names such as glargine, lantus, lispro, aspart, etc. Only English lan-
guage literature was considered for articles looking at the increased risk of cancer 
among type 2 diabetic patients using insulins. RESULTS: About 30 articles were 
selected, among those, 4 studies were conducted in humans using secondary database. 
All were historic cohort studies, and three used Cox regression for analysis. Two 
articles established a positive association between cancer incidence and insulin 
glargine, while the other two found no association. Three studies also showed that 
several insulins other than glargine are not associated with an increased risk of cancer. 
